Aerpio Pharmaceuticals, Inc.
ARPO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $7 | $23 |
| % Growth | – | -100% | -68.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $23 |
| % Margin | – | – | 0% | 99.4% |
| R&D Expenses | $14 | $49 | $9 | $25 |
| G&A Expenses | $0 | $0 | $0 | $8 |
| SG&A Expenses | $5 | $6 | $13 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $20 |
| Other Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Expenses | $20 | $55 | $22 | $53 |
| Operating Income | -$20 | -$55 | -$15 | -$36 |
| % Margin | – | – | -213% | -157.3% |
| Other Income/Exp. Net | $2 | $2 | $88 | $0 |
| Pre-Tax Income | -$18 | -$53 | $73 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18 | -$53 | $73 | -$14 |
| % Margin | – | – | 1,021.9% | -63.1% |
| EPS | -0.26 | -0.76 | 1.84 | -1.04 |
| % Growth | 65.8% | -141.3% | 276.9% | – |
| EPS Diluted | -0.26 | -0.76 | 2.7 | -1.04 |
| Weighted Avg Shares Out | 69 | 69 | 27 | 27 |
| Weighted Avg Shares Out Dil | 69 | 69 | 27 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $1 | $3 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$1 |
| EBITDA | -$18 | -$55 | -$15 | -$37 |
| % Margin | – | – | -213% | -160.2% |